Navigation Links
Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

NEW YORK, March 15, 2017 /PRNewswire/ --

NetworkNewsWire Editorial Coverage 

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn't appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (OTC: IMLFF) (InMed Profile), GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), AXIM® Biotechnologies, Inc. (OTC: AXIM) and OWC Pharmaceutical Research Corp. (OTC: OWCP). From multiple sclerosis symptoms to gastrointestinal problems and rare skin conditions, cannabinoids are increasingly demonstrating potential for a variety of medical conditions. The biotech companies developing and commercializing these new therapies are on a path to market stardom.

Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (InMed Profile), flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). INM-750 is the first treatment ever developed specifically for this disease. Although, as of now, there is no cure for EB, INM-750 has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and modulate keratin levels in the skin, with potentially regenerative and restorative effects. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects. InMed's second product candidate, INM-085, is targeting glaucoma and is also being developed for topical (eye drop) application. With an estimated 2.7 million patients in the U.S. and a global market exceeding $5 billion, INM-085 will be the first glaucoma treatment designed to be a multi-mechanism, multi-target of action therapy based on cannabinoids.

In addition to its innovative drug delivery systems, what sets InMed apart further is its groundbreaking, proprietary biosynthesis process for the manufacture of all 90+ known cannabinoids that occur naturally in the marijuana plant. This cost-effective, innovative approach has already proven successful at laboratory scale, and it is likely to make InMed a game-changer in the booming cannabinoid pharmaceutical market. Most biotech companies in the field, including giants such as GW Pharmaceuticals (NASDAQ: GWPH), focus on traditional cannabinoid extraction methods that require tons of marijuana plants and tens of millions of dollars in expenses. This costly process is also resource intensive, with various factors that can impact quality control, just to get the two most common cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The extraction of less common cannabinoids is even more expensive, making such traditional processing methods highly unfeasible.

But InMed's biosynthesis process, much like Eli Lilly's current method for making human insulin, can change all of that. The company's high-yield/low-cost approach will allow the industry to tap into the potential of cannabinoids present in marijuana plants by creating them in a laboratory setting in a safe and scalable manner. With its top-tier management and board, which includes Chief Scientific Officer and global leader in cannabinoid science Dr. Sazzad Hossain and Chief Medical Officer Ado Muhammed - a former senior member of GW Pharmaceuticals and a proven leader in the development of cannabinoid-based therapies, InMed has the right expertise, the right team and the right science to cause a major shift in the market and turn it into a billion-dollar business.

Another company that focuses on transdermal cannabinoid-based therapies with very encouraging results is Israel's OWC Pharmaceutical Research Corp. (OTCQB: OWCP). The company manufactures products for various conditions, including PTSD, multiple myeloma, migraines and psoriasis, and it is focused on the development and optimization of two proprietary delivery systems: a sublingual tablet and a topical compound. OWC's research efforts are spearheaded by Chief Science Officer Dr. Yehuda Baruh, former head of the medical cannabis program of the Israeli Ministry of Health for over 10 years. Last month, the company received Institutional Board Review approval to run safety testing on its topical cream for the treatment of psoriasis and related conditions, making it the first topical delivery mechanism and proprietary cannabinoid-based psoriasis formulation to be included in the NIH Registry.

Yet another innovative delivery method for cannabinoid-based therapies comes from AXIM® Biotechnologies, Inc. (OTCQB: AXIM). With a market cap of $490 million, AXIM® is a leading cannabinoid research and development company that focuses on creating pharmaceutical, cosmetic and nutraceutical products. Its pharmaceutical products target mostly pain, anxiety and spasticity, as well as other medical conditions that can benefit from cannabinoid-based treatments. Its flagship products both use an innovative delivery method, being manufactured in the form of chewing gum, including: CanChew® - a CBD-based controlled release product for the treatment of irritable bowel syndrome (IBS), and MedChew Rx - a CBD/THC combination currently undergoing clinical trials for the treatment of multiple sclerosis-associated pain and spasticity. The company recently announced the launch of a phase 2 clinical trial for CanChew Plus®, which enrolls 40 trial patients suffering from IBS.

Another successful cannabis biotech company, Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), has taken the process one step further, focusing on the development of novel synthetic cannabinoid treatments designed for transdermal delivery. With a market cap of more than $260 million and a stock price of over $20 per share, Zynerba is developing two proprietary therapies: a synthetic tetrahydrocannabinol pro-drug transdermal patch for peripheral neuropathic pain and fibromyalgia, and a transdermal synthetic cannabinoid gel for osteoarthritis, fragile X syndrome and refractory epilepsy. Earlier this year, the company launched an underwritten public offering of 2.8 million shares at $18 per share, with expected proceeds of over $50 million to continue funding the clinical development of its proprietary therapies.

As mentioned above, GW Pharmaceuticals plc (NASDAQ: GWPH) is a leading industry player and a clear example of a medical marijuana firm whose stock has been skyrocketing as a result of successfully isolating different cannabinoids from marijuana plants and turning them into efficient medical therapies. The UK-based biopharmaceutical company has discovered an oromucosal spray for multiple sclerosis spasticity, which is already being successfully marketed in dozens of countries. Furthermore, it has isolated another cannabinoid to be used for the treatment of epilepsy, which is currently in the final clinical trial states before approval, and the company is also developing other product candidates for a wide range of medical conditions such as tuberous sclerosis complex, Dravet syndrome, infantile spasms, Lennox-Gastaut syndrome, glioma and schizophrenia. The company's success in developing effective and innovative cannabinoid-based therapies over the last few years has earned it a market cap of more than $3 billion and a share price of over $120.

For more information on InMed Pharmaceuticals, Inc. (IMLFF) please visit:

About NetworkNewsWire 

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)

New York, NY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

DISCLAIMER: NetworkNewsWire (NNW) is a source of content listed above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer or comparison to the profiled issuer. FN Media Group, LLC (FNM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker-dealer/analyst/adviser, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. NNW's compensation disclosure is incorporated herein and appears in full at


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.

Media Contact
E-mail: FN Media Group, LLC -
Phone: +1(954)345-0611

SOURCE NetworkNewsWire
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
2. Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma
3. Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma
4. How These Biotech Stocks are Faring? -- bluebird bio, Opexa Therapeutics, Agios Pharma, and PTC Therapeutics
5. Global Life Science Microscopy Devices Market to Reach US$2.0 bn by 2024: Rise in Pharmaceutical and Biotechnology Research to Fuel Scope for Expansion, says TMR
6. Global Pharma and Biotech Dealmaking Royalty Rate Trends Report 2017 - Research and Markets
7. ExcipientFest Americas Showcases Pharma and Biotech Breakthroughs
8. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
9. Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
10. Cocoon Biotech Announces CEO, Dr. Ailis Tweed-Kent, Named to Boston Business Journals "2017 Women to Watch in Science and Technology" List
11. Developments in the Biotechnology Market
Post Your Comments:
(Date:5/22/2019)... ... ... The R3 Stem Cell Heroes Program is now including teachers in the nomination ... the program to help give back to military veterans, first responders and now teachers ... , Any teacher may be nominated at . The Heroes ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... For two ... of experts: the APDA Scientific Advisory Board for their annual meeting to ... the 2019-2020 academic year; and a group of researchers and neurologists with specialized interest ...
(Date:5/22/2019)... ... , ... Today OpsCompass, a leading SaaS-based cloud governance provider, ... location strengthens OpsCompass presence in the area and offers a new physical location ... cloud. This expansion is in response to the region-wide increased demand for enterprise ...
Breaking Medicine Technology:
(Date:5/22/2019)... ... May 22, 2019 , ... EY ... is a finalist for the Entrepreneur Of The Year® 2019 Award in ... programs in the U.S., the program recognizes entrepreneurs and leaders of high-growth companies ...
(Date:5/22/2019)... ... May 22, 2019 , ... Care to Care ... studying the economic impact of misdiagnosis of imaging procedures. According to Lisa Woods, ... interpretations of the diagnostic imaging their employees were receiving, including CT scans and ...
(Date:5/22/2019)... ... May 22, 2019 , ... ... health observance, National Lifestyle Medicine Week, to take place May 28 to June ... evidence-based therapeutic approaches of Lifestyle Medicine: a whole food, plant-predominant dietary lifestyle, regular ...
(Date:5/22/2019)... ... 22, 2019 , ... The Josh Bersin Academy, the world’s ... at Work, an Academy program developed in partnership with Virgin Pulse and focusing ... examples for creating a holistic corporate wellbeing program and suggestions for making a ...
(Date:5/22/2019)... Fla. (PRWEB) , ... May 22, 2019 , ... ... on Monday, May 20. The opening makes AdventHealth Ocala the only hospital in ... and now a pediatric inpatient unit for families in the area. The unit ...
Breaking Medicine News(10 mins):